TSX up after index logs fresh record high close
Director James Huang of Atara Biotherapeutics, Inc. (NASDAQ: NASDAQ:ATRA), a company with a market capitalization of $78.83 million, reported purchasing 55,000 shares of common stock on August 15, 2025. The shares were bought at a weighted average price of $12.1895, in a range from $11.83 to $12.44, for a total transaction value of $670,422. The purchase comes amid strong momentum, with the stock delivering returns of 52.66% over the past six months.InvestingPro analysis shows 11 additional key insights about ATRA’s financial health and growth prospects.
Following the transaction, Huang directly and indirectly owns 1,405,000 shares of Atara Biotherapeutics. These shares are held by Panacea Venture Healthcare Fund II, L.P. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd, the general partner of Panacea Venture Healthcare Fund II, L.P. The company trades at a P/E ratio of 20.98, with analysts expecting net income growth this year.
In other recent news, Atara Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for tabelecleucel (tab-cel) with priority review. This application is significant as it seeks approval for tab-cel as a monotherapy for patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. The FDA has set a target action date of January 10, 2026, for this application. In response to this development, Mizuho (NYSE:MFG) adjusted its price target for Atara Biotherapeutics from $18.00 to $16.00, maintaining an Outperform rating. This adjustment reflects a revised timeline for the potential U.S. launch of tab-cel, aligning with the FDA’s set date. Additionally, Atara resubmitted the BLA to address manufacturing facility observations previously noted by the FDA. Approval of tab-cel would mark the first FDA-approved therapy for this indication and could result in a $40 million milestone payment from Atara’s partner, Pierre Fabre Laboratories.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.